Literature DB >> 2619700

Anti-ischemic and membrane stabilizing activity of calmodulin inhibitors.

A Beresewicz1.   

Abstract

In the control perfused working rat hearts subjected to 25 min global ischemia, reperfusion resulted in a 50% recovery of the hemodynamic functions. A concentration-dependent improvement of this recovery and a reduction of the postischemic lactate dehydrogenase (LDH) release was caused by calmidazolium (CMZ), trifluoperazine (TFP), and chlorpromazine (CPZ) added prior to ischemia. The drugs were not effective when added only to the reperfusate. The concentrations of CMZ, TFP, and CPZ producing the half-maximal effects were 2.5 X 10(-9) M, 1.5 X 10(-7) M and 3 X 10(-7) M, respectively. Prolongation of the ischemic period caused a progressive deterioration of the functional recovery of the hearts while the total postischemic LDH release showed, at the same time, an initial gradual rise followed by a later decay. In untreated hearts the duration of ischemia resulting in 50% loss of hemodynamic function and in a maximal LDH release was 25 min. TFP (10(-6) M) and CMZ (10(-7) M) prolonged these times by 4-7 min and 5-10 min. respectively. TFP, CPZ, and CMZ protected the erythrocytes from osmotic hemolysis. The maximum anti-hemolytic activity was produced by 3 X 10(-6) M CMZ, 3 X 10(-5) M TFP, and 10(-4) CPZ. The concentration-dependency of this effect was not affected by low concentrations of sodium dodecyl sulphate (SDS). Neither TFP nor CMZ prevented the hemolysis produced by 10(-3) M SDS. It is concluded that the delay in the development of the ischemic injury produced by TFP and CMZ is due to the effects of these drugs as calmodulin antagonists rather than as membrane stabilizers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2619700     DOI: 10.1007/bf01906948

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  36 in total

1.  Calmodulin stimulates human platelet phospholipase A2.

Authors:  P Y Wong; W Y Cheung
Journal:  Biochem Biophys Res Commun       Date:  1979-09-27       Impact factor: 3.575

2.  Reperfusion injury: laboratory artifact or clinical dilemma?

Authors:  W G Nayler; J S Elz
Journal:  Circulation       Date:  1986-08       Impact factor: 29.690

3.  Phosphorylation and dephosphorylation of phosphorylase kinase in the perfused rat heart.

Authors:  T E McCullough; D A Walsh
Journal:  J Biol Chem       Date:  1979-08-10       Impact factor: 5.157

Review 4.  Amphipathic metabolites and membrane dysfunction in ischemic myocardium.

Authors:  P B Corr; R W Gross; B E Sobel
Journal:  Circ Res       Date:  1984-08       Impact factor: 17.367

5.  Prevention of reperfusion damage in working rat hearts by calcium antagonists and calmodulin antagonists.

Authors:  A J Higgins; K J Blackburn
Journal:  J Mol Cell Cardiol       Date:  1984-05       Impact factor: 5.000

6.  Impaired cardiac work and oxygen uptake after reperfusion of regionally ischaemic myocardium.

Authors:  G J Kannengiesser; L H Opie; T J van der Werff
Journal:  J Mol Cell Cardiol       Date:  1979-02       Impact factor: 5.000

7.  Possible role for calmodulin in calcium paradox-induced heart failure.

Authors:  S W Schaffer; R S Roy; J M McMcord
Journal:  Eur Heart J       Date:  1983-12       Impact factor: 29.983

Review 8.  Calmodulin plays a pivotal role in cellular regulation.

Authors:  W Y Cheung
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

9.  Low calcium reperfusion of ischemic myocardium.

Authors:  K I Shine; A M Douglas
Journal:  J Mol Cell Cardiol       Date:  1983-04       Impact factor: 5.000

Review 10.  Myocardial ischemia: the pathogenesis of irreversible cell injury in ischemia.

Authors:  J L Farber; K R Chien; S Mittnacht
Journal:  Am J Pathol       Date:  1981-02       Impact factor: 4.307

View more
  1 in total

1.  Signal transduction in myocardial ischaemia and reperfusion.

Authors:  A Lochner; E Tromp; R Mouton
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.